Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Monitoring of Heat Shock Response and Phenotypic Changes in Hepatocellular Carcinoma After Heat Treatment.

Zaimoku R, Miyashita T, Tajima H, Takamura H, Harashima AI, Munesue S, Yamamoto Y, Ninomiya I, Fushida S, Harada K.

Anticancer Res. 2019 Oct;39(10):5393-5401. doi: 10.21873/anticanres.13733.

PMID:
31570434
2.

Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice.

Yamamoto Y, Liang M, Munesue S, Deguchi K, Harashima A, Furuhara K, Yuhi T, Zhong J, Akther S, Goto H, Eguchi Y, Kitao Y, Hori O, Shiraishi Y, Ozaki N, Shimizu Y, Kamide T, Yoshikawa A, Hayashi Y, Nakada M, Lopatina O, Gerasimenko M, Komleva Y, Malinovskaya N, Salmina AB, Asano M, Nishimori K, Shoelson SE, Yamamoto H, Higashida H.

Commun Biol. 2019 Feb 25;2:76. doi: 10.1038/s42003-019-0325-6. eCollection 2019.

3.

Citrullinated Histone H3: Early Biomarker of Neutrophil Extracellular Traps in Septic Liver Damage.

Nomura K, Miyashita T, Yamamoto Y, Munesue S, Harashima A, Takayama H, Fushida S, Ohta T.

J Surg Res. 2019 Feb;234:132-138. doi: 10.1016/j.jss.2018.08.014. Epub 2018 Oct 10.

PMID:
30527465
4.

Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome.

Takada S, Miyashita T, Yamamoto Y, Kanou S, Munesue S, Ohbatake Y, Nakanuma S, Okamoto K, Sakai S, Kinoshita J, Makino I, Nakamura K, Tajima H, Takamura H, Ninomiya I, Fushida S, Ohta T.

In Vivo. 2018 Nov-Dec;32(6):1409-1417. doi: 10.21873/invivo.11393.

5.

Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression.

Higuchi T, Takeuchi A, Munesue S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Inatani H, Shimozaki S, Kato T, Aoki Y, Abe K, Taniguchi Y, Aiba H, Murakami H, Harashima A, Yamamoto Y, Tsuchiya H.

Cancer Med. 2018 May;7(5):1944-1954. doi: 10.1002/cam4.1438. Epub 2018 Mar 23.

6.

In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

El-Far AHAM, Munesue S, Harashima A, Sato A, Shindo M, Nakajima S, Inada M, Tanaka M, Takeuchi A, Tsuchiya H, Yamamoto H, Shaheen HME, El-Sayed YS, Kawano S, Tanuma SI, Yamamoto Y.

Oncol Lett. 2018 Apr;15(4):4627-4634. doi: 10.3892/ol.2018.7902. Epub 2018 Jan 29.

7.

Intestinal transepithelial permeability of oxytocin into the blood is dependent on the receptor for advanced glycation end products in mice.

Higashida H, Furuhara K, Yamauchi AM, Deguchi K, Harashima A, Munesue S, Lopatina O, Gerasimenko M, Salmina AB, Zhang JS, Kodama H, Kuroda H, Tsuji C, Suto S, Yamamoto H, Yamamoto Y.

Sci Rep. 2017 Aug 11;7(1):7883. doi: 10.1038/s41598-017-07949-4.

8.

Contribution of methylglyoxal to delayed healing of bone injury in diabetes.

Aikawa T, Matsubara H, Ugaji S, Shirakawa J, Nagai R, Munesue S, Harashima A, Yamamoto Y, Tsuchiya H.

Mol Med Rep. 2017 Jul;16(1):403-409. doi: 10.3892/mmr.2017.6589. Epub 2017 May 16.

PMID:
28534951
9.

Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer.

Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A, Harada S, Yamamoto H, Ohta T.

Oncol Rep. 2017 Jun;37(6):3341-3350. doi: 10.3892/or.2017.5586. Epub 2017 Apr 19.

PMID:
28440494
10.

Preventive Effect of Salicylate and Pyridoxamine on Diabetic Nephropathy.

Abouzed TK, Munesue S, Harashima A, Masuo Y, Kato Y, Khailo K, Yamamoto H, Yamamoto Y.

J Diabetes Res. 2016;2016:1786789. doi: 10.1155/2016/1786789. Epub 2016 Nov 30.

11.

Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma.

Takeuchi A, Yamamoto N, Shirai T, Hayashi K, Miwa S, Munesue S, Yamamoto Y, Tsuchiya H.

BMC Cancer. 2016 Jul 11;16:442. doi: 10.1186/s12885-016-2524-6.

12.

[AGE-RAGE system].

Harashima A, Munesue S, Yamamoto Y.

Nihon Rinsho. 2016 Apr;74 Suppl 2:49-52. Japanese. No abstract available.

PMID:
27266061
13.

Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination.

Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Munesue S, Harashima A, Harada S, Yamamoto H, Ohta T.

Gastric Cancer. 2016 Oct;19(4):1052-1065. doi: 10.1007/s10120-015-0579-8. Epub 2015 Nov 30.

14.

cAMP ameliorates inflammation by modulation of macrophage receptor for advanced glycation end-products.

Motoyoshi S, Yamamoto Y, Munesue S, Igawa H, Harashima A, Saito H, Han D, Watanabe T, Sato H, Yamamoto H.

Biochem J. 2014 Oct 1;463(1):75-82. doi: 10.1042/BJ20140084.

PMID:
24995813
15.

Thrombomodulin modulates dendritic cells via both antagonism of high mobility group protein B1 and an independent mechanism.

Toda M, D'Alessandro-Gabazza CN, Takagi T, Chelakkot-Govindalayathila AL, Taguchi O, Roeen Z, Munesue S, Yamamoto Y, Yamamoto H, Gabazza EC, Morser J.

Allergol Int. 2014 Mar;63(1):57-66. doi: 10.2332/allergolint.13-OA-0595. Epub 2013 Dec 25.

16.

Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury.

Sakai S, Tajima H, Miyashita T, Nakanuma S, Makino I, Hayashi H, Nakagawara H, Kitagawa H, Fushida S, Fujimura T, Saito H, Munesue S, Yamamoto Y, Ohta T.

Dig Dis Sci. 2014 Apr;59(4):787-94. doi: 10.1007/s10620-013-2963-8. Epub 2013 Dec 8.

PMID:
24318803
17.

Low-molecular weight fractions of Japanese soy sauce act as a RAGE antagonist via inhibition of RAGE trafficking to lipid rafts.

Munesue S, Yamamoto Y, Urushihara R, Inomata K, Saito H, Motoyoshi S, Watanabe T, Yonekura H, Yamamoto H.

Food Funct. 2013 Dec;4(12):1835-42. doi: 10.1039/c2fo30359k.

PMID:
24191276
18.

Validated Liquid Culture Monitoring System for Lifespan Extension of Caenorhabditis elegans through Genetic and Dietary Manipulations.

Win MT, Yamamoto Y, Munesue S, Han D, Harada S, Yamamoto H.

Aging Dis. 2013 Jun 17;4(4):178-85. Print 2013 Aug.

19.

Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells.

Takeuchi A, Yamamoto Y, Munesue S, Harashima A, Watanabe T, Yonekura H, Yamamoto H, Tsuchiya H.

Cancer Sci. 2013 Jun;104(6):740-9. doi: 10.1111/cas.12133. Epub 2013 Mar 24.

20.

Induction of receptor for advanced glycation end products by insufficient leptin action triggers pancreatic β-cell failure in type 2 diabetes.

Han D, Yamamoto Y, Munesue S, Motoyoshi S, Saito H, Win MT, Watanabe T, Tsuneyama K, Yamamoto H.

Genes Cells. 2013 Apr;18(4):302-14. doi: 10.1111/gtc.12036. Epub 2013 Feb 14.

21.

RAGE mediates vascular injury and inflammation after global cerebral ischemia.

Kamide T, Kitao Y, Takeichi T, Okada A, Mohri H, Schmidt AM, Kawano T, Munesue S, Yamamoto Y, Yamamoto H, Hamada J, Hori O.

Neurochem Int. 2012 Feb;60(3):220-8. doi: 10.1016/j.neuint.2011.12.008. Epub 2011 Dec 19.

PMID:
22202666
22.

Regulation of RAGE for attenuating progression of diabetic vascular complications.

Win MT, Yamamoto Y, Munesue S, Saito H, Han D, Motoyoshi S, Kamal T, Ohara T, Watanabe T, Yamamoto H.

Exp Diabetes Res. 2012;2012:894605. doi: 10.1155/2012/894605. Epub 2011 Oct 29. Review.

23.

Endogenous secretory receptor for advanced glycation end-products inhibits amyloid-β1-42 uptake into mouse brain.

Sugihara T, Munesue S, Yamamoto Y, Sakurai S, Akhter N, Kitamura Y, Shiba K, Watanabe T, Yonekura H, Hayashi Y, Hamada J, Yamamoto H.

J Alzheimers Dis. 2012;28(3):709-20. doi: 10.3233/JAD-2011-110776.

PMID:
22064071
24.

Septic shock is associated with receptor for advanced glycation end products ligation of LPS.

Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Motoyoshi S, Han D, Watanabe T, Asano M, Takasawa S, Okamoto H, Shimura S, Karasawa T, Yonekura H, Yamamoto H.

J Immunol. 2011 Mar 1;186(5):3248-57. doi: 10.4049/jimmunol.1002253. Epub 2011 Jan 26.

25.

Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells.

Takagi T, Taguchi O, Toda M, Ruiz DB, Bernabe PG, D'Alessandro-Gabazza CN, Miyake Y, Kobayashi T, Aoki S, Chiba F, Yano Y, Conway EM, Munesue S, Yamamoto Y, Yamamoto H, Suzuki K, Takei Y, Morser J, Gabazza EC.

Am J Respir Crit Care Med. 2011 Jan 1;183(1):31-42. doi: 10.1164/rccm.201001-0107OC. Epub 2010 Aug 13.

PMID:
20709825
26.

Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H.

Ohe K, Watanabe T, Harada S, Munesue S, Yamamoto Y, Yonekura H, Yamamoto H.

J Biochem. 2010 May;147(5):651-9. doi: 10.1093/jb/mvp207. Epub 2009 Dec 21.

PMID:
20028692
27.

Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice.

Sakatani S, Yamada K, Homma C, Munesue S, Yamamoto Y, Yamamoto H, Hirase H.

PLoS One. 2009 Dec 15;4(12):e8309. doi: 10.1371/journal.pone.0008309.

28.

RAGE in diabetic nephropathy.

Yamamoto H, Watanabe T, Yamamoto Y, Yonekura H, Munesue S, Harashima A, Ooe K, Hossain S, Saito H, Murakami N.

Curr Mol Med. 2007 Dec;7(8):752-7. Review.

PMID:
18331233
29.

Matrix metalloproteinase-9 associated with heparan sulphate chains of GPI-anchored cell surface proteoglycans mediates motility of murine colon adenocarcinoma cells.

Koyama Y, Naruo H, Yoshitomi Y, Munesue S, Kiyono S, Kusano Y, Hashimoto K, Yokoi T, Nakanishi H, Shimizu S, Okayama M, Oguri K.

J Biochem. 2008 May;143(5):581-92. doi: 10.1093/jb/mvn006. Epub 2008 Jan 23.

PMID:
18216069
30.

Differential expression of syndecan isoforms during mouse incisor amelogenesis.

Muto T, Miyoshi K, Munesue S, Nakada H, Okayama M, Matsuo T, Noma T.

J Med Invest. 2007 Aug;54(3-4):331-9.

31.

De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts.

Osawa M, Yamamoto Y, Munesue S, Murakami N, Sakurai S, Watanabe T, Yonekura H, Uchigata Y, Iwamoto Y, Yamamoto H.

Biochim Biophys Acta. 2007 Oct;1770(10):1468-74. Epub 2007 Jul 19.

PMID:
17714874
32.

A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis.

Munesue S, Yoshitomi Y, Kusano Y, Koyama Y, Nishiyama A, Nakanishi H, Miyazaki K, Ishimaru T, Miyaura S, Okayama M, Oguri K.

J Biol Chem. 2007 Sep 21;282(38):28164-74. Epub 2007 Jul 10.

33.

Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis.

Nakanishi H, Yasui K, Ikehara Y, Yokoyama H, Munesue S, Kodera Y, Tatematsu M.

Clin Exp Metastasis. 2005;22(2):137-47.

PMID:
16086234
34.

Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.

Yoshitomi Y, Nakanishi H, Kusano Y, Munesue S, Oguri K, Tatematsu M, Yamashina I, Okayama M.

Cancer Lett. 2004 Apr 30;207(2):165-74.

PMID:
15072825
35.
36.

The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones.

Munesue S, Kusano Y, Oguri K, Itano N, Yoshitomi Y, Nakanishi H, Yamashina I, Okayama M.

Biochem J. 2002 Apr 15;363(Pt 2):201-9.

37.

Identification of the core protein carrying the Tn antigen in mouse brain: specific expression on syndecan-3.

Akita K, Fushiki S, Fujimoto T, Munesue S, Inoue M, Oguri K, Okayama M, Yamashina I, Nakada H.

Cell Struct Funct. 2001 Oct;26(5):271-8.

38.

Supplemental Content

Loading ...
Support Center